Medicines labeled for the same conditions
Alternatives to berahyaluronidase alfa and pembrolizumab
5 other medicines are given the same way (subcutaneous) and in the same FDA class as berahyaluronidase alfa and pembrolizumab or labeled mainly for the same use (lung cancer); 5 are in its class, endoglycosidases: amivantamab and hyaluronidase, hyaluronidase and nivolumab, hyaluronidase and pertuzumab and trastuzumab, atezolizumab and hyaluronidase and 1 more (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as berahyaluronidase alfa and pembrolizumab?
Lung cancer lists all 55 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Berahyaluronidase alfa and pembrolizumabendoglycosidase | this medicine | none listed | n/a | No | No current entry |
| Amivantamab and hyaluronidaseendoglycosidase · same class | Lung cancer | none listed | n/a | No | No current entry |
| Hyaluronidase and nivolumabendoglycosidase · same class | Lung cancer | none listed | n/a | No | No current entry |
| Hyaluronidase and pertuzumab and trastuzumabher2/neu receptor antagonist · same class | Breast cancer | none listed | n/a | Yes | No current entry |
| Atezolizumab and hyaluronidaseendoglycosidase · same class | Lung cancer | none listed | n/a | No | No current entry |
| Hyaluronidase and trastuzumabher2/neu receptor antagonist · same class | Breast cancer | none listed | n/a | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Berahyaluronidase alfa and pembrolizumab: the full record
- label, generics, price, shortages, recalls